First Trust Advisors’s Anika Therapeutics ANIK Stock Holding History

First Trust Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-7,804	Closed	-$250K	–	2426
2018 Q2	$250K	Buy	+7,804	New	+$321K	﹤0.01%	2314
2017 Q2	–	Sell	-13,245	Closed	-$575K	–	2362
2017 Q1	$575K	Buy	13,245 +1,410	+12%	+$67.3K	﹤0.01%	2028
2016 Q4	$579K	Buy	+11,835	New	+$547K	﹤0.01%	2063
2016 Q2	–	Sell	-10,530	Closed	-$471K	–	2272
2016 Q1	$471K	Buy	+10,530	New	+$427K	﹤0.01%	1954
2015 Q3	–	Sell	-16,882	Closed	-$558K	–	2256
2015 Q2	$558K	Buy	+16,882	New	+$602K	﹤0.01%	1962
2015 Q1	–	Sell	-13,638	Closed	-$556K	–	2219
2014 Q4	$556K	Sell	13,638 -42,063	-76%	-$1.64M	﹤0.01%	1951
2014 Q3	$2.04M	Buy	55,701 +848	+2%	+$36.6K	0.01%	1375
2014 Q2	$2.54M	Sell	54,853 -21,271	-28%	-$946K	0.01%	1233
2014 Q1	$3.13M	Buy	76,124 +66,682	+706%	+$2.48M	0.01%	1159
2013 Q4	$360K	Sell	9,442 -6,359	-40%	-$196K	﹤0.01%	2004
2013 Q3	$377K	Buy	15,801 +1,320	+9%	+$29.6K	﹤0.01%	2019
2013 Q2	$246K	Buy	+14,481	New	+$209K	﹤0.01%	2089

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors's ANIK Position: Q3 2018 in Review

First Trust Advisors sold out of Anika Therapeutics (ANIK) in Q3 2018, closing a stake of 7,804 shares — an estimated $250K sold.

First Trust Advisors first reported a position in ANIK in Q2 2013 and held it in 12 quarters. The position peaked at $3.13M in Q1 2014. 161 funds tracked by Wall St. Rank hold ANIK as of Q3 2018.

First Trust Advisors reported no remaining Anika Therapeutics position as of Q3 2018 after selling out during the quarter.
First Trust Advisors sold 7,804 Anika Therapeutics shares in Q3 2018, an estimated $250K.
First Trust Advisors first reported a position in Anika Therapeutics in Q2 2013 and held it in 12 quarters.
First Trust Advisors's Anika Therapeutics position peaked at $3.13M in Q1 2014.
161 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2018.

Based on First Trust Advisors's 13F filing for Q3 2018, filed 25 Oct 2018.